AstraZeneca CEO Pascal Soriot (Raphael Lafargue/Abaca/Sipa USA)
A combo of AstraZeneca's Imfinzi and chemo wins where others have failed in pivotal biliary tract test
Looking to run with the big dogs in the PD-(L)1 class, AstraZeneca’s Imfinzi has a tall hill to climb to compete in an increasingly bustling …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
